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Abstract It has been long thought that neuronal loss in
Parkinson’s disease (PD) is related to reactive oxygen
species from mitochondrial dysfunction. However, there
have been few investigations surveying both transcriptome
and proteome in PD. This review focuses on recent work
using microarrays and mass spectrometry to examine
neurotoxicological models of PD in the mouse. Molecular
pathways involved in oxidative phosphorylation, oxidative
stress, apoptosis/cell death, signal transduction and neuro-
transmission were highlighted. Analysis of tyrosine nitra-
tion suggested that this important post-translational
modification, due to conjugation of reactive oxygen species
with nitric oxide, may play an important role in signal
transduction as well as the molecular pathology of PD.
Thus, the combined investigations highlight known path-
ways in PD but also point to new directions for research,
implicating particularly the role of relatively understudied
classes of post-translational modifications in normal cell
signaling and neurological disorders.
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Oxidative stress and Parkinson’s disease
Parkinson’s disease (PD) is the second most common cause
of neurological disability after Alzheimer’s disease (Tsang
and Chung 2009; Zhou et al. 2008). The disorder is charac-
terized by the tetrad of tremor, rigidity, bradykinesia and
postural instability, while the hallmark pathology is loss of
dopaminergic neurons in the nigrostriatal pathway. The
overwhelming majority of PD cases are sporadic, though rare
monogenic forms are known. Affected neurons frequently
contain eosinophilic inclusion bodies called Lewy bodies.
However, the mechanisms initiating neuronal pathology in
sporadic PD are largely obscure.
Studies of both humans and mouse models have impli-
cated a complex cascade of oxidative damage in PD (Lin and
Beal 2006). A principal source of this oxidative chain is the
mitochondrion, the main generator of superoxide radicals
(•O2
−). These radicals are produced as a byproduct of the
electron transport chain employed in oxidative phosphory-
lation. Complex I of the electron transport chain is
responsible for most of the burden. An intricate array of
mechanisms exists to efficiently mop up superoxide and
other reactive oxygen species (ROS). Superoxide dismutase
(SOD) converts •O2
− to hydrogen peroxide (H2O2), which
is subsequently converted into water and oxygen in a
reaction catalyzed by catalase and peroxiredoxin. However,
in Fenton’s reaction Fe2+ can catalyze the transformation of
H2O2 into the highly damaging hydroxide radical, •OH.
The oxidative stress associated with PD may also play a
direct role in the apoptosis of dopaminergic neurons, since
many of the components of the apoptotic cascade are redox
sensitive (Mattson 2000). Furthermore, mitochondrial dys-
function contributing to oxidative damage in PD may also
trigger apoptosis, since this organelle is intimately involved
in initiating programmed cell death (Zamzami and Kroemer
2001).
While the role of nitric oxide (•NO) as an essential
neurotransmitter is well established, this signaling molecule
can also be another source of neuronal oxidative damage
through production of reactive nitrogen species (RNS).
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Nitric oxide also mediates chronic inflammation, thus linking
inflammatory responses with oxidative injury. Conjugation
of •NO with •O2
− gives the reactive peroxynitrite (ONOO−),
which in turn gives rise to the damaging molecules nitrogen
dioxide (•NO2), •OH, or the carbonate radical •CO3
− (10–
12) (Beckman and Koppenol 1996; Reiter et al. 2000; Tien
et al. 1999). Importantly, ONOO− and •NO2 can conjugate
with the tyrosine sidechain to form nitrated tyrosine, a
modification that can potentially alter protein function and
modulate signal transduction (Radi 2004).
Transcriptomic and proteomic studies of mouse
models of PD
Despite the considerable circumstantial data suggesting an
important role for oxidative stress in PD, there was little
information on the concerted changes occurring in the
transcriptome and proteome in this disorder. In a recent
paper (Chin et al. 2008) microarrays and mass spectrometry
were used to investigate the transcriptome and proteome,
respectively, in the striatum of mouse models of PD. The
mouse models were created using the neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Vijitruth
et al. 2006) and toxic doses of methamphetamine (Melega
et al. 1997; Sonsalla et al. 1996) (Fig. 1). Using two inde-
pendent pharmacological models of PD enabled identifica-
tion of common themes, more likely representing core
pathways for PD, while effects restricted to either of the
drugs represent idiosyncratic drug reactions. MPTP exerts
its toxic effects through enzymatic conversion to the cation
1-methyl-4-phenylpyridinium (MPP+) by monoamine oxi-
dase B (MAOB) (Smeyne and Jackson-Lewis 2005). MPP+
is then specifically carried into dopaminergic neurons by
the dopamine transporter (DAT) where it inhibits complex I
of the mitochondrial electron transport chain. Inhibition of
mitochondrial respiration suffocates the dopaminergic
neuron, while further damage is inflicted by the resulting
onslaught of ROS.
The transcriptomic analysis employed Affymetrix arrays,
while the proteomic analysis used tryptic digestion of
proteins followed by liquid chromatography (LC) combined
with a time-of-flight, Fourier transform (FT) ion cyclotron
resonance (ICR) mass spectrometer (MS) (LC FTICR MS).
The MS instrumentation was operated using the accurate
mass and time (AMT) tag approach, in which peptide
identification was based not on the more common approach
of MS/MS fragmentation patterns, but on directly matching
LC-MS features with a pre-established AMT tag database
employing accurately measured LC elution time and mass
information (Liu et al. 2007; Zimmer et al. 2006). The LC
FTICR MS approach delivers high throughput capability to
analyze large sample numbers.
Relative peptide quantitation used 16O/18O ratios in which
a universal 18O-labeled internal standard was employed for
control samples. Trypsin-catalyzed exchange was used for
the labeling procedure (Qian et al. 2005). To greatly enhance
protein coverage, a cysteinyl-peptide enrichment (CPE)
strategy was employed, in which peptides were treated with
DTT followed by affinity purification on thiopropyl beads
and elution with additional DTT. This quantitative cysteinyl-
peptide enrichment technology (QCET) is a powerful
alternative to the widely-used Isotope-Coded Affinity Tags
(ICAT) method. Another benefit of merging 16O/18O
labeling and CPE for proteomic quantitation is that both
Cys- and non-Cys-peptides can be evaluated, in contrast to
ICAT, where only Cys-peptides are quantitated. The pooled
results from the Cys and non-Cys peptides improve
quantitation and enhance proteome coverage.
Mitochondrial dysfunction, oxidative stress
and apoptosis in PD striatum
A total of 1624 striatal proteins were quantitated using the
LC FTICR MS and AMT strategies, suggesting substantial
proteome coverage. Significant abundance changes were
found in 149 and 199 proteins as a result of METH and
MPTP treatment, respectively (p<0.05). The 215 most
strongly significant proteins are depicted in a heat map in
Fig. 2. A large percentage of proteins displayed consistent
abundance regulation in both the MPTP and METH-treated
mice. Consistent with this, relative protein abundance
changes in response to both neurotoxins were highly sig-
nificantly correlated, suggesting a commonality of mecha-
nism. Purkinje cell protein 4 (Pcp4) provided an illustration
of quantitation sensitivity, displaying a decrease of <30%
following MPTP, similar to that reported in the literature
(Skold et al. 2006).
The striatal transcriptome of the MPTP andMETH treated
mice were also analyzed using microarrays. Compared to
controls, the MPTP-treated striata showed 34 significantly
upregulated and 29 downregulated genes, while the METH-
treated striata showed 51 significantly upregulated and
Fig. 1 Structures of MPTP and
methamphetamine
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40 downregulated. Just as for the proteomics, there was
significant overlap between the two disease models with
highly significant correlations of relative transcript abun-
dance ratios.
Together, the transcriptomic and proteomic data revealed
that the expression of 195 genes was altered in the striatum
of the two models of PD, giving a more complete picture of
the pathways involved in this disorder. A number of
functional categories were prominent, including mitochon-
drial dysfunction, oxidative phosphorylation, oxidative
stress, apoptosis/cell death, signal transduction and neuro-
transmission. Genes downregulated in mice treated with
both neurotoxins included five subunits of complex I and
several ATP synthase subunits, consistent with a picture of
striatal mitochondrial dysfunction. Complex I deficiency
augments soluble mitochondrial reserves of cytochrome C1
(Perier et al. 2005). Consistently, levels of cytochrome C1,
a pro-apoptotic protein, were also elevated in MPTP-treated
mice. Furthermore, F-type ATPase complex levels were
diminished, concordant with mitochondrial dysfunction and
inhibited ATP generation. Also decreased were levels of
V-type ATPase, involved in fueling synaptic vesicles with
neurotransmitters.
Adding to the landscape of oxidative stress, antioxidant
gene products (Gpx4 and Gstm5), and gene products
potentially regulated in response to oxidative damage
(Dusp1 and Fos) exhibited decreased abundance, while
oxidative stress response proteins (PI3K, Usp14 and Rras2)
were induced (Goldshmit et al. 2001; Lee et al. 1999).
Surveying endogenously nitrated proteins
using proteomics
Since •NO can combine with ROS to cause nitration of
tyrosine residues, nitrated tyrosines were sought by searching
the normal mouse brain AMT database for peptides with
tyrosines containing an supplementary mass equivalent to an
added NO2 (Sacksteder et al. 2006). A total of 29 unique
proteins were found with nitrotyrosine modifications.
Approximately 0.4% of total proteins were nitrated, consis-
tent with the known high in vivo selectivity of tyrosine
nitration (Ischiropoulos 2003). Of the nitrotyrosines, 11 of
the modifications were on residues known to be targets of
tyrosine kinases, suggesting the possibility that the nitration
may play a role in normal signal transduction.
The nitrated tyrosines were found on highly abundant
proteins, such as tubulin and actin as well as proteins
expressed at very low levels, such as receptors and nuclear
transcription factors. The identified proteins usually had
low nitration levels, with a range of <1 to 50%. Consistent
with the role of the mitochondrion in providing ROS, there
was an ~2–3-fold proteins. More than half of the identified
nitrated proteins had previously been associated with
neurodegenerative disorders such as PD or Alzheimer’s
disease through altered transcript levels, protein abundance
or gene mutation. Furthermore, the presence of nitrated
proteins in normal brain was confirmed by Western blots of
brain proteins using antibodies recognizing nitrotyrosine.
Increased levels of nitrated proteins were found in MPTP
treated brain, suggesting a role for nitration in PD.
Fig. 2 Alterations in protein abundance of MA and MPTP-treated
striata compared to vehicle treated controls. The 215 proteins with
significant changes displayed. Columns show relative quantities of
individual samples, while rows represent different proteins
Fig. 3 Tyrosine 269 (Y) of creatine kinase B chain presented on
exposed loop. This residue is nitrated in brain. Protein structure
downloaded from Protein Data Bank (www.pdb.org, PDB ID: 1QH4)
(Berman et al. 2000) and presented using ProteinWorkshop 3.5, part
of the Molecular Biology Toolkit (Moreland et al. 2005)
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Scrutiny of the nitrated protein sequences revealed an
increased frequency of basic amino acids near nitrated tyro-
sines, indicating that a positive charge enhances tyrosine
nitration. Both methionines and cysteines were found close to
nitrotyrosines, opposing the notion that tyrosine nitration is
impeded by competition from these residues (Ischiropoulos
1998; Zhang et al. 2005). Furthermore, available and
predicted three-dimensional structures from the set of
nitrated proteins revealed that nitrated tyrosines showed a
strong preference for accessibility and were often on the
surface of loops (Fig. 3).
The ER chaperone, glucose-regulated protein 78
(GRP78), and the eukaryotic initiation factor 2 (EIF2),
each essential in the unfolded protein response, were both
nitrated. Nitration may thus encourage the formation of
protein inclusion bodies such as Lewy bodies. Tyrosine
hydroxylase (TH) catalyzes the rate-limiting step of
dopamine synthesis and diminished dopamine production
due to decreased tyrosine hydroxylase activity is an early
event in PD. TH is activated by the TH activation protein, a
14-3-3 interaction protein, which binds and stabilizes the
active Ser40-phosphorylated form of TH. In contrast, TH
inactivation occurs via the phosphatase, PP2a, which is
itself activated by binding with α-synuclein, a protein
mutated in a monogenic form of PD and a component of
the Lewy body (Peng et al. 2005). The TH activation
protein was nitrated on two tyrosines. The endogenous
nitration of the TH activation protein found using the
proteomic approach, together with the known MPTP-
induced nitration of both TH and α-synuclein, implies a
hub of nitration activity potentially illuminating the early
dopamine deficits in the inflammatory and oxidative
damage models of PD (Przedborski et al. 2001; Uversky
et al. 2005; Yamin et al. 2003).
The importance of the nitrated proteins for normal neuronal
function combined with the observation that nitration sites
are sequence-dependent and often loci for phosphorylation
implies that nitrotyrosine modification should be considered
as a mechanism for normal cell signaling and also a causal
factor in neurodegenerative disease.
Conclusions
Although tantalizing glimpses of possible mechanistic
connections at the nexus of the mitochondrion, oxidative
stress and PD have been revealed by current studies, it is
clear that our understanding of this complex interplay is
only in its infancy. On the other hand, the power of
sensitive and high-throughput technologies to view the
transcriptome and proteome will continue to improve for
the foreseeable future. Phenomena such as alternative
splicing, variant transcriptional initiation and termination
sites as well as hitherto unimagined secondary protein
modifications will eventually reveal the entire pathway of
damage in PD, from initial molecular insult to final neuro-
logical disorder.
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